Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...

The dispensing of opioid agonists is often restricted to specialised treatment programmes. Credit: Your Hand Please via ...

AstraZeneca has reported positive results from a Phase III trial that evaluated Truqap combined with abiraterone and ADT for ...

MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.

The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous HBV)-specific TCR-T therapy, ...

Cybersecurity is another critical issue, as health data is particularly vulnerable to breaches, which can lead to identity ...

The biopharmaceutical industry is being called to take its sustainability efforts to the next level. A new report sheds light ...

The Global Coalition for Adaptive Research (GCAR) has executed an agreement to evaluate AstraZeneca's AZD1390 in the GBM ...